Diffusion Pharmaceuticals Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2020; filed August 7, 2020. The filing identifies the registrant as Diffusion Pharmaceuticals Inc., notwithstanding the request metadata naming Cervomed Inc.
Business context and results
Diffusion is a clinical-stage biotechnology company developing trans sodium crocetinate (TSC), intended to improve oxygen delivery to hypoxic tissue. Its programs include COVID-19, stroke and glioblastoma; the company is also evaluating options for RES-529. It has no product revenue and expects continuing losses.
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| R&D expense | $2.17 million | $1.52 million | $3.71 million | $3.22 million |
| G&A expense | $1.46 million | $1.07 million | $2.85 million | $2.27 million |
| Net loss | $3.13 million | $2.50 million | $5.68 million | $5.24 million |
| Net loss attributable to common stockholders | $5.08 million | $2.50 million | $7.63 million | $5.24 million |
| Operating cash flow | Not separately presented quarterly | $(6.65) million | $(5.27) million |
Q2 operating expenses rose $1.04 million year over year; six-month operating expenses rose $1.07 million. Management attributed higher R&D principally to COVID-19 trial preparation and manufacturing, and GBM trial follow-up, partly offset by lower stroke-trial costs amid pandemic-related delays. G&A increases were mainly professional fees. Margins are not meaningful because the company has no revenue.
Financial position and capital
- Cash and cash equivalents were $25.56 million at June 30, 2020, up from $14.18 million at December 31, 2019. Working capital was $24.9 million; accumulated deficit was $97.4 million.
- Six-month financing cash flow was $18.03 million, primarily from $10.8 million gross proceeds from stock and warrants and $8.0 million from warrant exercises, less $0.8 million of financing costs.
- Total liabilities were $3.12 million, including $1.78 million current liabilities. Disclosed liabilities include operating leases; the filing does not identify interest-bearing debt or credit facilities.
- May 2020 equity offering: 11.43 million shares at $1.05 per share, generating $10.3 million net proceeds. Shares outstanding increased from 33.48 million at year-end to 64.00 million at June 30.
Outlook, risks and unusual items
- Management believed June-end cash would fund operations into Q4 2021, but stated further funding is needed to complete planned trials. No committed additional capital was available; failure to raise funds could force delays, reductions, partnerships, strategic alternatives or cessation of operations.
- The company planned to begin a 24-patient open-label Phase 1b COVID-19 lead-in in Q3 2020, with a Q4 2020 data readout target. A larger program of approximately 400 patients was contingent on positive lead-in results and regulatory approvals. The IND was submitted July 7, 2020 and remained under FDA review at the time described.
- The Phase 2 stroke trial was enrolling, but near-term enrollment was expected to be minimal due to COVID-19. The Phase 3 INTACT GBM randomization phase depended on a strategic partnership and sufficient resources.
- COVID-19 had disrupted trial enrollment and operations; further delays to enrollment, sites, suppliers or regulatory review could raise costs and affect development. The filing said the pandemic had not materially affected financial-statement estimates through June 30.
- A May warrant exercise generated a $1.95 million deemed dividend, increasing the loss attributable to common stockholders but not net loss. Outstanding warrants and options also create potential dilution.
- A former-CEO dispute was scheduled for arbitration in November 2020. The company considered it without merit but could not estimate a possible loss; an adverse outcome could materially affect its financial position.
Important facts for investors to verify
- Subsequent FDA action on the COVID-19 IND, actual trial commencement, enrollment and results versus stated targets.
- Cash burn, funding runway and the amount and terms of any future financing or strategic partnership.
- Progress and pandemic-related enrollment effects in the stroke trial, and the funding path for the GBM Phase 3 trial.
- Potential dilution from outstanding warrants, options and future equity financing.
- Outcome and potential financial exposure from the pending arbitration.